Integra LifeSciences (NASDAQ:IART) Shares Up 9.1% – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares traded up 9.1% during mid-day trading on Monday. The company traded as high as $13.97 and last traded at $13.91. Approximately 566,782 shares changed hands during trading, a decline of 39% from the average session volume of 922,816 shares. The stock had previously closed at $12.75.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. decreased their price objective on shares of Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating for the company in a research note on Thursday, October 22nd. Citigroup reissued an “outperform” rating on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Wells Fargo & Company set a $13.00 target price on shares of Integra LifeSciences and gave the company an “equal weight” rating in a research note on Thursday, October 22nd. Finally, Citizens Jmp reduced their target price on shares of Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a report on Thursday, October 22nd. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has an average rating of “Reduce” and an average target price of $16.12.

Integra LifeSciences Trading Up 8.7%

The firm has a fifty day moving average of $14.71 and a 200 day moving average of $14.09. The firm has a market capitalization of $1.15 billion, a PE ratio of 87.18, a P/E/G ratio of 0.53 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a quick ratio of 2.21 and a current ratio of 3.62.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. The company had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. During the same period in the prior year, the company posted ($0.07) EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.34 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Paradigm Capital Management Inc. NY bought a new position in Integra LifeSciences during the 2nd quarter worth approximately $61,766,000. Wellington Management Group LLP grew its position in shares of Integra LifeSciences by 12.4% in the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after acquiring an additional 160,814 shares in the last quarter. Bank of America Corp DE grew its position in shares of Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Finally, Access Investment Management LLC increased its holdings in shares of Integra LifeSciences by 39.5% in the 3rd quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company’s stock valued at $9,198,000 after acquiring an additional 159,980 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.